Table 2.
Clinical trials of BiTE
| Drugs | Combination therapy | Target | Indication | Administration route | Case | Status | Adverse event | ID | Ref |
|---|---|---|---|---|---|---|---|---|---|
| MCLA 117 | No | CLEC12A | AML | NR | 50 | Phase 1 | NR | NCT03038230 | |
| AMG 330 | No | CD33 | AML | 0.5-960 µg/day cIV infusion in cycles from 14 to 28 days | 100 | Phase 1 | NR | NCT02520427 | |
| AMG673 | No | CD33 | AML | A short term intravenous (IV) infusion | 50 | Phase 1 | NR | NCT03224819 | |
| JNJ-63709178 | No | CD128 | AML | NR | 120 | Phase 1 | NR | NCT02715011 | |
| AMG 420 | No | BCMA | MM | Continuous intravenous infusion | 42 | Phase 1 | Infections, polyneuropathy, edema | NCT02514239 | [83] |
| MT110 | No | EpCAM | EpCAM-positive solid tumors | Continuous intravenous infusion | 65 | Phase 1 | Primarily diarrhea, elevated liver parameters, and elevated lipase | NCT00635596 | [84] |
| MEDI-565 | No | CEA | Gastrointestinal Adenocarcinomas | NR | 78 | Phase 1 | Diarrhea, CRS, increased alanine aminotransferase, hypertension, and hypoxia | NCT01284231 | [85] |
| AMG 211 | No | CEA | Gastrointestinal Adenocarcinomas | NR | 39 | Phase 1 | NR | NCT02291614 | |
| AMG 211 | No | CEA | Gastrointestinal Adenocarcinomas | NR | 9 | Phase 1 | NR | NCT02760199 | |
| AMG 757 | Pembrolizumab | DLL3 | SCLC | Intravenous infusion once every 2 weeks | 132 | Phase 1 | NR | NCT03319940 | |
| AMG 596 | No | EGFRvIII | Glioblastoma | NR | 200 | Phase 1 | NR | NCT03296696 | |
| BAY2010112 | No | PSMA | Prostate cancer | Be given daily as subcutaneous injection or as continuous intravenous infusion | 47 | Phase 1 | Influenza-like Symptoms, fatigue, decreased lymphocyte counts and infections (both in 44%) | NCT01723475 |
NR, not reported; MM, multiple myeloma; SCLC, small cell lung cancer; AML, acute myelocytic leukemia.